Cargando…

Investigation of Tumor Heterogeneity Using Integrated Single-Cell RNA Sequence Analysis to Focus on Genes Related to Breast Cancer-, EMT-, CSC-, and Metastasis-Related Markers in Patients with HER2-Positive Breast Cancer

Human epidermal growth factor receptor 2 (HER2) protein, which is characterized by the amplification of ERBB2, is a molecular target for HER2-overexpressing breast cancer. Many targeted HER2 strategies have been well developed thus far. Furthermore, intratumoral heterogeneity in HER2 cases has been...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shiino, Sho, Tokura, Momoko, Nakayama, Jun, Yoshida, Masayuki, Suto, Akihiko, Yamamoto, Yusuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527746/ https://www.ncbi.nlm.nih.gov/pubmed/37759508 http://dx.doi.org/10.3390/cells12182286

Ejemplares similares

Locally advanced triple negative breast cancer arising from fibroadenoma with complete response to neoadjuvant chemotherapy: A case report
por: Shiino, Sho, et al.
Publicado: (2020)

Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer
por: Sanomachi, Tomomi, et al.
Publicado: (2023)

Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
por: Shikata, Shohei, et al.
Publicado: (2023)

Spontaneous regression of occult breast cancer with axillary lymph node metastasis: A case report
por: Takayama, Shin, et al.
Publicado: (2019)

Interplay of EMT and CSC in Cancer and the Potential Therapeutic Strategies
por: Tanabe, Shihori, et al.
Publicado: (2020)

A prediction model for distant metastasis after isolated locoregional recurrence of breast cancer
por: Murata, Takeshi, et al.
Publicado: (2023)

Breast Cancer Brain Metastasis—Overview of Disease State, Treatment Options and Future Perspectives
por: Watase, Chikashi, et al.
Publicado: (2021)

Development and validation of a pre- and intra-operative scoring system that distinguishes between non-advanced and advanced axillary lymph node metastasis in breast cancer with positive sentinel lymph nodes: a retrospective study
por: Murata, Takeshi, et al.
Publicado: (2022)

Preliminary experiences of PET/MRI in predicting complete response in patients with breast cancer treated with neoadjuvant chemotherapy
por: Sekine, Chikako, et al.
Publicado: (2022)

Zebrafish Microenvironment Elevates EMT and CSC-Like Phenotype of Engrafted Prostate Cancer Cells
por: Chen, Lanpeng, et al.
Publicado: (2020)

Prognostic significance of receptor expression discordance between primary and recurrent breast cancers: a meta-analysis
por: Shiino, Sho, et al.
Publicado: (2021)

Impact of adjuvant chemotherapy and radiotherapy on tumour-infiltrating lymphocytes and PD-L1 expression in metastatic breast cancer
por: Yazaki, Shu, et al.
Publicado: (2022)

Cancer stem cell heterogeneity: origin and new perspectives on CSC targeting
por: Eun, Kiyoung, et al.
Publicado: (2017)

Assessment of nuclear grade-based recurrence risk classification in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive high-risk early breast cancer
por: Murata, Takeshi, et al.
Publicado: (2023)

A Metabolic Smorgasbord Drives and Sustains CSC Heterogeneity
por: Kahn, Michael
Publicado: (2023)

CSC
Publicado: (1996)

Targeting the Sonic Hedgehog Pathway to Suppress the Expression of the Cancer Stem Cell (CSC)—Related Transcription Factors and CSC-Driven Thyroid Tumor Growth
por: Lu, Yurong, et al.
Publicado: (2021)

Dissecting the biological heterogeneity of HER2-positive breast cancer
por: Schettini, Francesco, et al.
Publicado: (2021)

HER2 Intratumoral Heterogeneity in Breast Cancer, an Evolving Concept
por: Hou, Yanjun, et al.
Publicado: (2023)

HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer
por: Hosonaga, Mari, et al.
Publicado: (2018)

Oncogenic functions of the EMT-related transcription factor ZEB1 in breast cancer
por: Wu, Hua-Tao, et al.
Publicado: (2020)

An EMT-Related Gene Signature to Predict the Prognosis of Triple-Negative Breast Cancer
por: Zhang, Bo, et al.
Publicado: (2023)

SPARC mediates metastatic cooperation between CSC and non-CSC prostate cancer cell subpopulations
por: Mateo, Francesca, et al.
Publicado: (2014)

A tissue microRNA signature that predicts the prognosis of breast cancer in young women
por: Hironaka-Mitsuhashi, Ai, et al.
Publicado: (2017)

FAP, CD10, and GPR77-labeled CAFs cause neoadjuvant chemotherapy resistance by inducing EMT and CSC in gastric cancer
por: Zhao, Zehua, et al.
Publicado: (2023)

Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1
por: Nonagase, Yoshikane, et al.
Publicado: (2016)

The role of EMT-related lncRNA in the process of triple-negative breast cancer metastasis
por: Zhang, Haomeng, et al.
Publicado: (2021)

Blockade of Wnt/β-catenin signaling suppresses breast cancer metastasis by inhibiting CSC-like phenotype
por: Jang, Gyu-Beom, et al.
Publicado: (2015)

CD24 regulates cancer stem cell (CSC)-like traits and a panel of CSC-related molecules serves as a non-invasive urinary biomarker for the detection of bladder cancer
por: Ooki, Akira, et al.
Publicado: (2018)

Maternal breast cancer risk in relation to birthweight and gestation of her offspring
por: Swerdlow, Anthony J., et al.
Publicado: (2018)

Pruritus Related to Trastuzumab and Pertuzumab in HER2+ Breast Cancer Patients
por: Gu, Stephanie, et al.
Publicado: (2023)

Heterogeneity and plasticity of epithelial–mesenchymal transition (EMT) in cancer metastasis: Focusing on partial EMT and regulatory mechanisms
por: Li, Dandan, et al.
Publicado: (2023)

An In Vitro Approach to Model EMT in Breast Cancer
por: Isert, Lorenz, et al.
Publicado: (2023)

Establishment and Analysis of an Individualized EMT-Related Gene Signature for the Prognosis of Breast Cancer in Female Patients
por: Xue, Wei, et al.
Publicado: (2022)

Mitochondrial Fission Factor (MFF) Inhibits Mitochondrial Metabolism and Reduces Breast Cancer Stem Cell (CSC) Activity
por: Sánchez-Alvarez, Rosa, et al.
Publicado: (2020)

Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2019)

TRAF6 regulates tumour metastasis through EMT and CSC phenotypes in head and neck squamous cell carcinoma
por: Chen, Lei, et al.
Publicado: (2017)

Development of a Non‐Coding‐RNA‐based EMT/CSC Inhibitory Nanomedicine for In Vivo Treatment and Monitoring of HCC
por: Guo, Ruomi, et al.
Publicado: (2019)

Phenotypic heterogeneity driven by plasticity of the intermediate EMT state governs disease progression and metastasis in breast cancer
por: Brown, Meredith S., et al.
Publicado: (2022)

Differential Effects of Drugs Targeting Cancer Stem Cell (CSC) and Non-CSC Populations on Lung Primary Tumors and Metastasis
por: Larzabal, Leyre, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_5v4usj1qigod2i3r94ffbq5ift